Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron Deykin

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
BMC Neurology|January 1, 2015
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosisDouglas L Arnold, Peter A Calabresi, Bernd C Kieseier, et al.
The Lancet. Neurology|May 6, 2014
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyPeter A Calabresi, Bernd C Kieseier, Douglas L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2014
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCEBernd C Kieseier, Douglas L Arnold, Laura J Balcer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2020
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoringPeter A Calabresi, Douglas L Arnold, Dipen Sangurdekar, et al.
The Lancet. Neurology|March 17, 2018
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extensionRaju Kapoor, Pei-Ran Ho, Nolan Campbell, et al.
American Journal of Respiratory and Critical Care Medicine|December 3, 2005
beta-Adrenergic receptor polymorphisms and response to salmeterolMichael E Wechsler, Erik Lehman, Stephen C Lazarus, et al.
The Journal of Allergy and Clinical Immunology|April 5, 2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroidsAaron Deykin, Stephen C Lazarus, John V Fahy, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2006
Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthmaAaron Deykin, Michael E Wechsler, Homer A Boushey, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
The Journal of Allergy and Clinical Immunology|January 9, 2007
The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trialRichard J Martin, Stanley J Szefler, Tonya S King, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
BMC Neurology|January 1, 2015
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosisDouglas L Arnold, Peter A Calabresi, Bernd C Kieseier, et al.
The Lancet. Neurology|May 6, 2014
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyPeter A Calabresi, Bernd C Kieseier, Douglas L Arnold, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2014
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCEBernd C Kieseier, Douglas L Arnold, Laura J Balcer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2020
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoringPeter A Calabresi, Douglas L Arnold, Dipen Sangurdekar, et al.
The Lancet. Neurology|March 17, 2018
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extensionRaju Kapoor, Pei-Ran Ho, Nolan Campbell, et al.
American Journal of Respiratory and Critical Care Medicine|December 3, 2005
beta-Adrenergic receptor polymorphisms and response to salmeterolMichael E Wechsler, Erik Lehman, Stephen C Lazarus, et al.
The Journal of Allergy and Clinical Immunology|April 5, 2005
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroidsAaron Deykin, Stephen C Lazarus, John V Fahy, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2006
Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthmaAaron Deykin, Michael E Wechsler, Homer A Boushey, et al.
The Lancet. Neurology|July 10, 2019
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Michelle Mellion, Raymond Hupperts, et al.
The Journal of Allergy and Clinical Immunology|January 9, 2007
The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trialRichard J Martin, Stanley J Szefler, Tonya S King, et al.
Pageof 4